Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ChiRex (CHRX) -- Ignore unavailable to you. Want to Upgrade?

To: m meixlER who wrote (96)	1/22/1998 1:31:00 AM
From: yosi s	Read Replies (1) \| Respond to of 130

play back # is no longer valid I listened to its replay and spoke with ir.. The reason for the write off were related to getting rid off acetaminophene. apparently when the phenols were taken out of the system they needed to add oxygen to the system so the bacteria will stay alive and that cost them money. also some of the products that they are working on run into manufactoring snags and cost more to produce,They are doing some work that the drug companies were suppose to do, this will be negotiated and hopefully they can get some better pricing in the future . these are growing pains . the company may be able to recuperate some of those costs. Also they said they were stretch too thin . error in manufactoring were done. Going forward their core products are increasing so their gross margins are up ?35% in 98 glaxo deal stars to come in 50000 and this should bring gross reveues to 135000 if my memory serves me right this year revenues wre at 95000 that is a 50% up. also new facility nice room to grow. they got some more people and are recruting more; long term looks great. it looks like short term snag and price fell back a little but still nice come back from its low. The market overpunishes every little error. does not defferenciate from growing difficulties in a growth company to down sizing and decline in mature company.